Drugs / Lcr Regenerans
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02251093 | May 2014 → Feb 2016 | vulvovaginal candidiasis | Probionov | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lcr Regenerans | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02251093 ↗ |
| Action | Inhibit | “to inhibit the growth of pathogenic organisms responsible for causing bacterial vaginosis (Gardnerella vaginalis and Prevotella bivia) but also for mycoses (Candida albicans),...” NCT02251093 ↗ |
| Modality | Other / unclassified | “Lactobacillus rhamnosus Lcr35® is a live bacterium administered with its culture medium.” NCT02251093 ↗ |
| Route | Other | “Route of administration: intravaginal” NCT02251093 ↗ |